Allergan PLC (NYSE:AGN)

The share price exhibited an overall upward trajectory with notable volatility throughout the period examined. Beginning at $29.55 in March 2006, the price experienced modest fluctuations until 2013. From 2013 onward, a pronounced surge occurred, peaking at $298.07 in 2016. This peak was followed by a significant decline over the next two years, reaching a low of $139.07 in early 2019, before recovering somewhat to $198 by February 2020.

Operating profit per share showed considerable instability and a downward trend over the years. Initially positive at $1.97 in 2006, it turned negative in 2007 but then briefly recovered, peaking at $4.22 in 2012. After this peak, a steady deterioration ensued, with the figure turning negative again in 2014 and continuing to decline substantially, hitting a low of -$18.78 in 2019 before a slight improvement to -$13.51 in 2020. This indicates increasing operational challenges or higher costs relative to earnings over this timeframe.

The price to operating profit ratio (P/OP) similarly reflected volatility and some missing data points, limiting comprehensive analysis. Early values indicate a low ratio around 15.01 in 2006, followed by a dip to 11.43 in 2008 and a rise to 33.93 in 2013, suggesting periods of both undervaluation and overvaluation relative to operating profit. However, the absence of data beyond 2013 prevents identifying trends concurrent with the declining operating profit per share in subsequent years.

Overall, the financial indicators reveal a complex picture: while the market price of shares drastically increased, particularly in the middle years of the period, underlying operating profitability deteriorated significantly. This divergence may suggest market optimism or external factors influencing share price beyond operational performance. The decline in operating profit per share and incomplete P/OP data in later years warrants further investigation into the company’s operational efficiency and market valuation drivers.